ADT May Decrease Risk of COVID-19 in Men With Prostate Cancer, Study Finds
TMPRSS2, a serine protease expressed in prostate and lung tissue that is necessary for SARS-CoV-2 viral infectivity of host cells, is activated by the androgen receptor.
Androgen-deprivation Therapy
Nonadherence to Abiraterone or Enzalutamide for Metastatic CRPC May Be More Common in Frail Patients
This observational cohort study found that BAAS questionnaire is not a suitable tool for monitoring whether older patients with mCRPC are adherent to their antiandrogen therapy; however, pill counting was effective.
Investigating the Role of Salvage Lymph Node Dissection in Nonmetastatic CRPC
Traditionally, approaches to the management of patients with nonmetastatic CRPC following radical prostatectomy have been limited.
Early ADT for Recurrent Prostate Cancer Challenged
Men with biochemically recurrent nonmetastatic prostate cancer following radical prostatectomy have long survival times from the time of surgery without hormonal treatment, a study found.
ASCO Releases Guideline on Addressing Osteoporosis Risk With Nonmetastatic Cancer
The guideline includes strategies to identify patients with nonmetastatic cancer who may be at a higher risk for osteoporotic fractures.
Prostate Cancer ADT Raises Dementia Risk, Study Finds
Androgen deprivation therapy for prostate cancer is associated with a significant 20% increased risk of dementia and 14% increased risk of Alzheimer’s disease, a study found.
Non-Standard Therapies Used in 20% of Localized High-Risk PCa Cases
Using EBRT alone or ADT alone for high-risk localized prostate cancer is associated with worse survival outcomes.
Lower Testosterone Threshold May Benefit ADT Recipients
New study shows prolonged time to development of castration-resistant prostate cancer among men with absolute testosterone levels below 20 ng/dL.
Low Carb Diet + Walking May Ease ADT’s Adverse Effects
In a small study, men on androgen deprivation therapy for prostate cancer lost weight and experienced improved hemoglobin A1C and lipid profiles.
Prostate Cancer ADT May Reduce Autoimmune Disease Risk
Androgen deprivation therapy recipients had a significantly lower risk for autoimmune diseases overall and for Graves’ disease, uveitis, and psoriasis.
-
Loading...
-
Loading...
Next post in Prostate Cancer
